logo
Twitter
Discord
Email
logo
NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Company N.V.

NASDAQ•NAMS
CEO: Dr. Michael Harvey Davidson FACC, Facp., M.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2021-02-09
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Contact Information
Gooimeer 2-35, Naarden, 1411 DC, Netherlands
31-35-206-2971
www.newamsterdampharma.com
Market Cap
$4.22B
P/E (TTM)
-20.0
42.1
Dividend Yield
--
52W High
$42.00
52W Low
$14.06
52W Range
83%
Rank57Top 72.6%
2.8
F-Score
Modified Piotroski Analysis
Based on 5-year fundamentals
Weak • 2.8 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2020-2024

Financial Dashboard

Q3 2025 Data

Revenue

$348.00K-98.80%
4-Quarter Trend

EPS

-$0.61+238.89%
4-Quarter Trend

FCF

-$32.81M+160.88%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Net Loss Reduction Net loss decreased $20.5M for nine months ended September 30, 2025, driven by revenue timing shifts and cost management.
R&D Revenue Recognition Recognized $16.1M revenue from second development cost contribution, partially offsetting prior milestone revenue drop recognized in 2024.
R&D Expense Decline Research and development expenses decreased $13.3M for nine months, primarily due to completion of several Phase 3 clinical trials.
SG&A Cost Increase SG&A expenses rose $29.6M for nine months, driven by $22.9M personnel costs and share-based compensation arrangements.

Risk Factors

Revenue Timing Dependency Nine month revenue dropped $10.3M due to non-recurrence of large clinical milestone revenue recognized in the prior year period.
High Accumulated Deficit Accumulated loss reached $687.5M as of September 30, 2025; continued significant losses expected for foreseeable future operations.
Warrant Exercise Uncertainty Potential proceeds up to $29.8M from outstanding Warrants are highly dependent on share price, risking expiration worthless.
Regulatory/Pricing Headwinds Future legislation, especially regarding drug pricing and reimbursement, could adversely affect commercial opportunity and revenue realization.

Outlook

CVOT Trial Progress PREVAIL cardiovascular outcomes trial completed enrollment; earliest conclusion expected by the end of 2026 timeframe for MACE events.
European Regulatory Review Marketing Authorization Applications for obicetrapib validated by EMA in August 2025 for review across European territories.
Cash Position Sufficiency Cash reserves of $539.7M as of September 30, 2025, are deemed sufficient to fund current obligations and planned activities.
Future Financing Needs Expect continued significant losses; ability to raise additional capital on acceptable terms remains critical for future operations.

Peer Comparison

Revenue (TTM)

Arrowhead Pharmaceuticals, Inc.ARWR
$596.57M
+2936.3%
Protagonist Therapeutics, Inc.PTGX
$209.22M
-35.4%
Soleno Therapeutics, Inc.SLNO
$98.68M
+2763.5%

Gross Margin (Latest Quarter)

Soleno Therapeutics, Inc.SLNO
98.3%
+0.0pp
NewAmsterdam Pharma Company N.V.NAMS
81.6%
-18.4pp
Arcellx, Inc.ACLX
78.6%
-16.9pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
ARWR$9.69B-65.7-41.2%51.7%
KYMR$6.45B-26.5-33.4%7.6%
PTGX$5.95B132.36.9%1.5%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-69.9%
Growth Under Pressure
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Next earnings:Feb 25, 2026
|
EPS:-$0.40
|
Revenue:-
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 5, 2025|
    Revenue: $348.00K-98.8%
    |
    EPS: $-0.61+238.9%
    Miss

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 6, 2025|
    Revenue: $19.15M+740.1%
    |
    EPS: $-0.15-60.5%
    Beat

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 8, 2025|
    Revenue: $2.98M+112.6%
    |
    EPS: $-0.34-65.3%
    Beat

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 26, 2025|
    Revenue: $45.56M+257.0%
    |
    EPS: $-2.56-19.1%
    Miss

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 6, 2024|
    Revenue: $29.11M+1450.7%
    |
    EPS: $-0.18-67.9%
    Beat

  • Form 20-F/A - FY 2022

    Period End: Dec 31, 2022|Filed: Oct 28, 2024|
    Revenue: $95.91M+0.0%
    |
    EPS: $-1.11+66.8%
    Miss

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 7, 2024|
    Revenue: $2.28M+44.8%
    |
    EPS: $-0.38-11.6%
    Beat

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 8, 2024|
    Revenue: $1.40M-82.4%
    |
    EPS: $-0.98+108.5%
    Miss